EA201591304A1 - Применение комплекса, облегчающего транскрипцию хроматина (fact), при раке - Google Patents

Применение комплекса, облегчающего транскрипцию хроматина (fact), при раке

Info

Publication number
EA201591304A1
EA201591304A1 EA201591304A EA201591304A EA201591304A1 EA 201591304 A1 EA201591304 A1 EA 201591304A1 EA 201591304 A EA201591304 A EA 201591304A EA 201591304 A EA201591304 A EA 201591304A EA 201591304 A1 EA201591304 A1 EA 201591304A1
Authority
EA
Eurasian Patent Office
Prior art keywords
fact
complex
cancer
enabling
application
Prior art date
Application number
EA201591304A
Other languages
English (en)
Other versions
EA036615B1 (ru
Inventor
Катерина ГУРОВА
Original Assignee
ИНКУРОН ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ИНКУРОН ЭлЭлСи filed Critical ИНКУРОН ЭлЭлСи
Publication of EA201591304A1 publication Critical patent/EA201591304A1/ru
Publication of EA036615B1 publication Critical patent/EA036615B1/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Настоящее изобретение относится inter alia к определению по меньшей мере одного компонента комплекса, облегчающего транскрипцию хроматина (FACT), для оценки опухоли, включая, например, определение агрессивности опухоли и назначение лечения.
EA201591304A 2013-02-11 2014-02-11 Применение комплекса, облегчающего транскрипцию хроматина (fact), при раке EA036615B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361763266P 2013-02-11 2013-02-11
US201361883802P 2013-09-27 2013-09-27
PCT/US2014/015854 WO2014124454A1 (en) 2013-02-11 2014-02-11 Use of facilitates chromatin transcription complex (fact) in cancer

Publications (2)

Publication Number Publication Date
EA201591304A1 true EA201591304A1 (ru) 2016-01-29
EA036615B1 EA036615B1 (ru) 2020-11-30

Family

ID=51300203

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591304A EA036615B1 (ru) 2013-02-11 2014-02-11 Применение комплекса, облегчающего транскрипцию хроматина (fact), при раке

Country Status (7)

Country Link
US (1) US10386370B2 (ru)
EP (1) EP2954331B1 (ru)
JP (1) JP6576249B2 (ru)
CN (1) CN104981697B (ru)
EA (1) EA036615B1 (ru)
HK (1) HK1218953A1 (ru)
WO (1) WO2014124454A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108333366B (zh) * 2018-01-26 2020-06-12 南通大学附属医院 一种实验性监测肝细胞恶性转化过程大鼠模型的建立方法
CN109136376B (zh) * 2018-05-21 2021-09-21 中国医科大学附属第四医院 一种膀胱癌相关环状RNA的应用和siRNA及其用途
CN113721020B (zh) * 2021-09-14 2022-06-24 大连医科大学附属第二医院 Ctsf在非小细胞肺癌诊断中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2715680A1 (de) 1977-04-07 1978-10-12 Henkel Kgaa Haarfaerbemittel
ATE529535T1 (de) 2002-03-13 2011-11-15 Genomic Health Inc Genexpressionsprofilierung in einer biopsie unterzogenem tumorgewebe
AU2003272175A1 (en) 2002-10-21 2004-05-04 Aprea Ab Reactivation of wild type p53 in human tumour cells by a low molecular weight compound
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
ES2690168T3 (es) 2003-06-24 2018-11-19 Genomic Health, Inc. Predicción de la probabilidad de recidiva de cáncer
EP1644858B1 (en) 2003-07-10 2017-12-06 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
US7169802B2 (en) 2003-12-23 2007-01-30 Cephalon, Inc. Fused pyrrolocarbazoles
US20100047783A1 (en) 2006-06-20 2010-02-25 El-Diery Wafik S Small molecule modulators of p53 family signaling
WO2009055823A2 (en) * 2007-10-26 2009-04-30 Progen Pharmaceuticals Limited Method to predict responsiveness of breast cancer to polyaminetype chemotherapy
EP2288741B1 (en) 2008-05-14 2015-01-28 University Health Network Prognostic and predictive gene signature for non-small cell lung cancer and adjuvant chemotherapy
WO2009143290A2 (en) 2008-05-20 2009-11-26 Cleveland Biolabs, Inc Inducing cell death by inhibiting adaptive heat shock response
US20100081666A1 (en) 2008-07-14 2010-04-01 Wyeth Src activation for determining cancer prognosis and as a target for cancer therapy
UA107652C2 (en) 2008-10-06 2015-02-10 Incuron Llc Carbazole compounds and therapeutic uses of the compounds
US20100331210A1 (en) 2009-05-29 2010-12-30 Precision Therapeutics, Inc. Methods and systems for evaluating the sensitivity or resistance of tumor specimens to chemotherapeutic agents
US9169207B2 (en) 2012-03-27 2015-10-27 Incuron, Llc Curaxins for use in treating carcinogen-induced cancer
US20140066465A1 (en) 2012-09-04 2014-03-06 The Cleveland Clinic Foundation CANCER TREATMENT USING TYROSINE KINASE AND NF-kB INHIBITORS

Also Published As

Publication number Publication date
CN104981697A (zh) 2015-10-14
HK1218953A1 (zh) 2017-03-17
EA036615B1 (ru) 2020-11-30
JP6576249B2 (ja) 2019-09-18
US10386370B2 (en) 2019-08-20
WO2014124454A1 (en) 2014-08-14
US20160033515A1 (en) 2016-02-04
EP2954331A1 (en) 2015-12-16
JP2016514248A (ja) 2016-05-19
EP2954331B1 (en) 2018-03-28
EP2954331A4 (en) 2016-08-31
CN104981697B (zh) 2017-08-04

Similar Documents

Publication Publication Date Title
CY1122510T1 (el) Μορια αντισωματος σε lag-3 και χρησεις αυτων
GEP20217331B (en) Anti-tigit antibodies
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
DK3277842T3 (da) Fremgangsmåder til at behandle kræftpatienter med farnesyl-transferase-inhibitorer
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
DK3033086T3 (da) Kombinationsterapi til behandling af cancer
EP3119908A4 (en) Determining cancer aggressiveness, prognosis and responsiveness to treatment
MX2016002826A (es) Anticuerpos anti-b7-h1 para tratar tumores.
EA201691214A1 (ru) Антитела к cd33 и иммуноконъюгаты
EA201690617A1 (ru) Комбинирование anti-lag-3-антител и анти-pd-1-антител для лечения опухолей
MX2016001963A (es) Metodo de seleccion.
EA201591340A1 (ru) Модулятор андрогенного рецептора и его применения
MY178726A (en) Combination therapy of an afucosylated cd20 antibody with a btk inhibitor
EA201400178A1 (ru) Лечение рака молочной железы
KR20180084772A (ko) 암 치료를 위한 조합 치료법
EA201690513A1 (ru) Комбинация ингибитора mek и ингибитора erk для применения в лечении гиперпролиферативных заболеваний
EA201591705A1 (ru) Композиции и способы для диагностики и лечения рака печени
BR112013024211A2 (pt) tratamento de tumores sólidos
EA201790312A1 (ru) Комбинации лекарственных средств для лечения множественной миеломы
HK1256042A1 (zh) 用於治療糖尿病周圍神經病變的hdac抑制劑
EA201591399A1 (ru) РАППγ АГОНИСТЫ ДЛЯ ЛЕЧЕНИЯ РАССЕЯННОГО СКЛЕРОЗА
DK2988760T3 (da) C. novyi til behandlingen af faste tumorer i mennesker
MX2016015163A (es) Biomarcadores mit y metodos para su uso.
JO3541B1 (ar) علاجات طبية قائمة على اناموريلين
EA201691108A1 (ru) Хиназолин-thf-амины в качестве ингибиторов pde1

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM